Carl Zeiss Meditec Faces Sharp Analyst Downgrades Following Quarterly Results

Major banks slash targets for Carl Zeiss Meditec as disappointing Q1 results and weak markets in China & US lead to a guidance withdrawal and index demotion.

The recent demotion from Germany's MDAX index was a significant blow for Carl Zeiss Meditec. The situation has now intensified, with a wave of prominent financial institutions slashing their price targets for the medical technology firm in the wake of disappointing quarterly figures. In the most drastic adjustment, UBS cut its target by half to 25.00 euros—a level the stock nearly touched in Tuesday's trading session.

Operational Performance Declines

The erosion of analyst confidence stems from clear operational challenges. For the first quarter of the current fiscal year, ending December 2025, the company's operating profit plummeted to 8.1 million euros from 35.2 million euros in the prior-year period. This collapse caused the EBITA margin to sink to 1.7%, down from 7.2%. Revenue also contracted by 4.8% to 467 million euros.

Market experts point to two primary headwinds. In China, a government bulk procurement initiative for intraocular lenses, known as Volume-Based Procurement, is applying sustained downward pressure on pricing. Concurrently, weak capital investment appetite in the United States, another core market, is further hampering performance.

These developments prompted management to withdraw its full-year guidance in January, merely weeks after issuing it. The company has yet to provide a new forecast.

Market Experts React with Lowered Targets

The analytical community has responded with a consensus of downward revisions:

• UBS (Analyst Graham Doyle): Price target reduced from 53.00 € to 25.00 €.
• Barclays: Maintained an "Equal Weight" rating but set a new target of 30.00 €.
• Bernstein Research: Estimated fair value at 28.50 €.

While these targets remain above Tuesday's closing price of 23.38 euros, they underscore the stock's precipitous decline. Since reaching a 52-week high of 69.35 euros in March 2025, the share price has shed approximately two-thirds of its value.

Index Shift and the Path Forward

The stock's move from the MDAX to the SDAX, effective March 23, added further selling pressure. The rebalancing forced passively managed exchange-traded funds (ETFs) to adjust their holdings, boosting trading volume on Monday and briefly pushing shares below 24.00 euros.

Investor attention now turns to May 12, 2026, when Carl Zeiss Meditec is scheduled to release its half-year report. The company has committed to presenting a new annual outlook alongside specific restructuring measures at that time. Until then, visibility for shareholders remains limited, suggesting continued volatility in the trading range.